RALEIGH, N.C., Aug. 4 /PRNewswire/ -- CLOSURE Medical Corporation
(Nasdaq: CLSR), a medical tissue cohesive products company announced today
that it has been awarded its first United States Patent relevant to its lead
product, DERMABOND Topical Skin Adhesive. U.S. Patent No. 5,928,611, entitled
"Impregnated Applicator Tip," was issued on July 27, 1999.
"The invention covered in this patent capitalizes on the ability of our
adhesive technology to be manipulated in a manner that enhances product
performance by controlling the setting time and extending the shelf life of
the material," said Debra L. Pawl, Vice President and General Counsel.
"This invention represents an exciting new capability to modify product
characteristics for synthetic monomer materials, such as octyl cyanoacrylates,
and we fully expect to continue to exploit this breakthrough in new product
development projects," added J. Blount Swain, Chief Financial Officer.
DERMABOND Topical Skin Adhesive is marketed by Ethicon, Inc., a subsidiary
of Johnson & Johnson, under an exclusive worldwide supply and distribution
agreement.
CLOSURE Medical Corporation, headquartered in Raleigh, N.C., develops,
manufactures and commercializes medical tissue cohesive products based on its
proprietary cyanoacrylate technology. CLOSURE's nonabsorbable tissue cohesive
products may be used to replace sutures and staples for certain topical wound
closure applications, while its absorbable tissue cohesive products can
potentially be used as tissue cohesives for internal wound closure and
management. Currently marketed nonabsorbable tissue cohesive products include
DERMABOND Topical Skin Adhesive, which is used to replace sutures and staples
for closure of certain lacerations and incisions, OCTYLDENT(R) cohesive, which
is used as an adjunct in the treatment of adult periodontal disease; and
NEXABAND(R) topical cohesives, a family of products used in veterinary wound
closure and management.
DERMABOND is a trademark of Ethicon, Inc.; SOOTHE-N-SEAL, OCTYLDENT and
NEXABAND are all trademarks of CLOSURE Medical Corporation.
To receive CLOSURE's latest news release and other corporate documents via
fax, at no cost, call 1-800-PRO-INFO, use the Company's symbol CLSR. Or visit
the Financial Relations Board's website at http://www.frbinc.com .
This release contains certain forward-looking statements which involve
known and unknown risks, delays, uncertainties or other factors not under the
Company's control which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance, or
other expectations implied by these forward-looking statements. These factors
include, but are not limited to the early stage of commercialization of the
Company products; the progress of its research and development programs for
future nonabsorbable and absorbable products; the need for regulatory approval
and effects of governmental regulation; technological uncertainties;
dependence on marketing partners, and dependence on patents and trade secrets,
as well as those detailed in the Company's Annual Report on Form 10-K for the
year ended December 31, 1998 filed with the Securities and Exchange
Commission.
SOURCE CLOSURE Medical Corporation
 back to top
Related links:
http://www.frbinc.com
CONTACT:
Robert V. Toni, President & CEO, or J. Blount
Swain, CFO, CLOSURE Medical Corporation, 919-876-7800; or
General, Paul G. Henning, Analyst, Brian Gill, Media, Deanne
Eagle of The Financial Relations Board, 212-661-8030
|
